Articles from Flashpoint Therapeutics

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicine, announced today the publication of foundational research demonstrating the power of its proprietary Spherical Nucleic Acid (SNA) platform to create highly potent and targeted cancer therapies. The study, published in the journal ACS Nano by a team led by Flashpoint’s scientific co-founder Professor Chad A. Mirkin at the International Institute for Nanotechnology at Northwestern University, reports results of research with a new chemotherapeutic SNA that selectively targets and eliminates acute myeloid leukemia (AML) cells in preclinical models.

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the publication of a study entitled “A general genome editing strategy using CRISPR lipid nanoparticle spherical nucleic acids” in the Proceedings of the National Academy of Sciences during the week of September 1, 2025.

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical phases of growth, development, and commercialization.

Flashpoint Therapeutics, a company developing nanotechnology-enabled therapeutics for cancer and other diseases, announced today a $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with participation from leading private equity investor Russell Carson’s CS Venture Opportunities Fund.